Inhibitors of apoptosis proteins (IAPS) as potential molecular targets for therapy of hematological malignancies

Current Molecular Medicine

Volumn 11, Issue 8, 2011, Pages 633-649

  Smolewski, P ^a   Robak, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Hematological malignancies; IAPs; Inhibitor of apoptosis proteins; Therapies

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 2 AMINOTHIAZOLE; AEG 35156; AEG 40730; AEG 40826; ALISERTIB; AT 406; BERBERINE; BORTEZOMIB; CASPASE; CD38 ANTIGEN; CELASTROL; CONDITIONALLY REPLICATING ADENOVIRUS; CYTARABINE; DOXORUBICIN; EMBELIN; FLUDARABINE; GATAPARSEN; INHIBITOR OF APOPTOSIS PROTEIN; LBW 242; MELPHALAN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PENTOXIFYLLINE; SURVIVIN; TERAMEPROCOL; THIOCOLCHICOSIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CARCINOGENESIS; CELL DIVISION; CELL SURVIVAL; ENZYME ACTIVITY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOCYTOSIS; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; REVIEW;

ANIMALS; APOPTOSIS; HEMATOLOGIC NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, LYMPHOID; LYMPHOMA; MODELS, BIOLOGICAL;

INTRACISTERNAL A-PARTICLES;

EID: 80053987575     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411797536723     Document Type: Review

References (186)

1. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 1995; 6: 3-16.
2. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30.
3. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 1992; 11: 95-103.
4. Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol 2001; 2: 545-50.
5. Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007; 4: 63-71.
6. Smolewski P, Darzynkiewicz Z, Robak T. Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications. Leuk Lymphoma 2003; 44: 1089-104.
7. Pluta A, Nyman U, Joseph B, et al. The role of p73 in hematological malignancies. Leukemia 2006; 20: 757-66.
8. Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol 2001; 2: 550-6.
9. Schliep S, Decker T, Schneller F, Wagner H, Hacker G. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp Hematol 2004; 32: 556-62
10. Brown CE, Murphy TH. Livin' on the edge: imaging dendritic spine turnover in the peri-infarct zone during ischemic stroke and recovery. Neuroscientist 2008; 14(2):139-46.
11. Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta A, et al. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 2004; 9: 705-15.
12. Nakagawa Y, Yamaguchi S, Hasegawa M, et al. Differential expression of surviving in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 2004; 28: 487-4.
13. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-83.
14. de Graaf AO, van Krieken JH, Tonnissen E, et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005; 130: 852-9.
15. Akyurek N, Ren Y, Rassidakis GZ, et al. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006; 107: 1844-51.
16. Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003; 304: 499-504.
17. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specifi c caspases. EMBO J 1997; 16: 6914-25.
18. Vousden KH, Prives C: P53 and prognosis: new insights and further complexity. Cell 2005; 120: 7-10.
19. Yang Y, Fang S, Jensen JP, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288: 874-7.
20. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-68.
21. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrom c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
22. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001; 2: 30091-10.
23. Sun C, Cai M, Meadows RP, et al. NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein. XIAP J Biol Chem 2000; 275: 33777-81.
24. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10.
25. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6(4): 287-97.
26. Lu M, Lin SC, Huang Y, et al. XIAP induced NF-kappaB activation via BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007; 26: 689-702.
27. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001; 98: 8662-7.
28. Wang CY, Mayo MW, Korneluk RG, et al. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-3.
29. Chu ZL, McKinsey TA, Liu L, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997; 94: 10057-62.
30. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-46.
31. Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008-12.
32. Saelens X, Festjens N, Vande Walle L, et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004; 23: 2861-74.
33. Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ 2008; 15: 453-60.
34. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem 2004; 279: 16963-70.
35. Wang S. Design of small-molecule Smac mimetics as IAP antagonists. Vassilew L, Fry D (Eds). Small molecule inhibitors of protein-protein interaction. In curr Topics Microbiol Immunol 2011; 384: 89-113.
36. van Loo G, van Gurp M, Depuydt B, et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ 2002; 9: 20-6.
37. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
38. Arora V, Cheung HH, Plenchette S, et al. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. Biol Chem 2007; 282: 26202-9.
39. Silva KL, Vasconcellos DV, Castro ED, et al. Apoptotic effect of fl udarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 2006; 11: 277-85.
40. Vallat L, Magdelenat H, Merle-Beral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 2003; 101: 4598-606.
41. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in Bcell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002; 100: 3749-56.
42. Zent CS, Zhan F, Schichman SA, et al. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res. 2003; 27: 765-74.
43. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010; 46: 800-10.
44. Bilim V, Kasahara T, Hara N, et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003; 103: 29-37.
45. Hu Y, Cherton-Horvat G, Dragowska V. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9: 2826-36.
46. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231-3.
47. Morgan JA, Yin Y, Borowsky AD, et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999; 59: 6205-13.
48. Varfolomeev E, Wayson SM, Dixit VM, et al. The inhibitor of apoptosis protein fusion c-IAP2MALT1 stimulates NFkappaB activation independently of TRAF1 AND TRAF2. J Biol Chem 2006; 281: 29022-9.
49. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601-9.
50. Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade Bcell lymphoma of mucosaassociated lymphoid tissue. Oncogene 1999; 18: 5785-94.
51. Small S, Keerthivasan G, Huang Z, et al. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia 2010; 24: 1920-6.
52. Adida C, Haiooun C, Gaulard O, et al. Prognostic significance of surviving expression in diffuse large B-cell lymphoma. Blood 2000; 96: 1021-25
53. Paydas S, Ergin M, Seydaoglu G, et al. Prognostic [corrected] significance of angiogenic/lymphangiogenic, antiapoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 2009; 33: 1627-35.
54. Schlette EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004; 22: 1682-8.
55. Mitrović Z, Ilić I, Aurer I, et al. Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP. Pathol Oncol Res 2010 Sep 18 [Epub ahead of print].
56. Hussain AR, Uddin S, Ahmed M, et al. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol 2010; 222: 180-90.
57. Liu L, Zhang M, Zou P. Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 2179-83.
58. Markovic O, Marisavljevic D, Cemerikic V, et al. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large b cell lymphoma (DLBCL). Eur J Haematol 2010 Dec 30 [Epub ahead of print].
59. Martinez A, Bellosillo B, Bosch F, et al. Nuclear surviving expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164: 501-10.
60. Rezaei N, Mahmoudi E, Aghamohammadi A, et al. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011; 152: 13-30.
61. Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods 2010; 362: 1-9.
62. Lu J, Murakami M, Verma SC, et al. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 2011; 410: 64-75.
63. Ren Y, Akyurek N, Schlette E, et al. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol 2006; 37: 1407-13.
64. Zyada MM. Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region. Med Oncol 2010 Jun 4 [Epub ahead of print]
65. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101: 681-9.
66. Messineo C, Jamerson MH, Hunter E, et al. Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood 1998; 91: 2443-51.
67. Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol
68. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res, 2000; 6:1796-803.
69. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004; 10: 3737-44.
70. Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pancaspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003; 102: 4179-86.
71. Carter BZ, Milella M, Altieri DC, Andreeff M: Cytokineregulated expression of survivin in myeloid leukemia. Blood 2001; 97: 2784-90.
72. Tamm I, Richter S, Scholz F, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004; 5: 489-95
73. Guenova ML, Balatzenko GN, Nikolova VR, et al. An antiapoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene Hematology 2010; 15: 135-43.
74. Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res 2010; 34: 1308-13.
75. Balkhi MY, Christopeit M, Chen Y, Geletu M, Behre G. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp Hematol 2008; 36: 1455-66.
76. Fukuda S, Abe M, Onishi C, et al. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol 2011; 2011: doi:10.1155/2011/946936. Epub 2010 Dec 23.
77. Yamamoto K, Abe S, Nakagawa Y, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 2004; 28: 1203-11.
78. Badran A, Yoshida A, Wano Y, et al. Expression of the antiapoptotic gene survivin in myelodysplastic syndrome. Int J Oncol 2003; 22: 59-64.
79. Abe S, Yamamoto K, Hasegawa M, et al. Bone marrow cells of myelodysplastic syndromes exhibit significant expression of apollon, livin and ILP-2 with reduction after transformation to overt leukemia. Leuk Res 2005; 29: 1095-6.
80. Sung KW, Choi J, Hwang YK, et al. Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res 2007; 13: 5109-14.
81. Troeger A, Siepermann M, Escherich G, et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007; 92: 1043-50.
82. Che XF, Zheng CL, Owatari S, et al. Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood 2006; 107: 4880-7.
83. Hundsdoerfer P, Dietrich I, Schmelz K, et al. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer 2010; 55: 260-6.
84. Choi J, Hwang YK, Sung KW, et al. Expression of livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007; 109: 471-7.
85. Yang YL, Lin SR, Chen JS, et al. Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia. Leuk Res 2010; 34: 18-23.
86. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
87. Pui CH, Behm FG, Downing JR, et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-15.
88. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-93.
89. Chen G-H, Lin F-R, Ren J-H, et al. Expression and significance of X-linked inhibitor of apoptosis protein and its antagonized proteins in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14: 639-43.
90. Xu L, Zhu J, Hu X, et al. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell 2007; 28: 914-22.
91. Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81: 824-31.
92. Nachmias B, Ashhab Y, Bucholtz V, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drugresistant melanoma. Cancer Res 2003; 63: 6340-9.
93. Romagnoli M, Trichet V, David C, et al. Significant impact of survivin on myeloma cell growth Leukemia 2007; 21: 1070-8.
94. Wang X, Zhang Z, Yao C. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res 2010; 34: 1325-9.
95. Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S Impact of XIAP protein levels on the survival of myeloma cells. Haematologica 2009; 94(1): 87-93
96. Badran A, Yoshida A, Wano Y, et al. Expression of the antiapoptotic gene surviving in chronic myeloid leukemia. Anticancer Res 2003; 23: 589-92.
97. Hasegawa T, Suzuki K, Sakamoto C, et al. Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colonystimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 2003; 101: 1164-71.
98. Flygare JA, Fairbrother WJ. Small-molecule paan-IAP antagonists; a patent review. Expert Opin Ther Patents 2010; 20: 251-67.
99. Wang Z, Sampath J, Fukuda S, Pelus LM. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-ablpositive cells to STI571-induced apoptosis. Cancer Res 2005; 65: 8224-32.
100. LaCasse EC, Kandimalla ER, Winocour P, et al. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Ann N Y Acad Sci 2005; 1058: 215-34.
101. Carter BZ, Milella M, Tsao T, et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003; 17: 2081-9.
102. Lima RT, Martins LM, Guimaraes JE, et al. Chemosensitization effects of XIAP downregulation in K562 leukemia cells. J Chemother 2006; 18: 98-102.
103. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting Xlinked inhibitor of apoptosis. Clin Cancer Res 2006; 12: 5231-41.
104. LaCasse E, Morris S, Ward T, et al. AEG 35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolatedd from pre-clinical models and from patients. 97th American Association Cancer Research Annual Meeting Washington, DC 2006.
105. Sasaki Y, Minamizawa M, Ambo A, et al. Cell-penetrating peptide-conjugated XIAP-inhibitory cyclic hexapeptides enter into Jurkat cells and inhibit cell proliferation. FEBS J 2008; 275: 6011-21.
106. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 13: 179-88.
107. Carter BZ, Mak DH, Morris SJ, et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38 (-) cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2010 Oct 12 [Epub ahead of print].
108. Jolivet J, Dean E, Ward T, et al. A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. J Clin Oncol (Meeting Abstr) 2008; 26: 3541.
109. Frenzel LP, Patz M, Pallasch CP, et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis Br J Haematol 2011; 152: 191-200.
110. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004; 18: 616-23.
111. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. I Drugs 2008; 11: 204-14.
112. Tolcher AW, Antonia S, Lewis LD, et al. A phase I study of YM155, a novel survivin uppressant, administered by 168 h continuous infusion to patients with advanced solid tumors. J Clin Oncol (Meeting Abstr) 2006; 24: 3014.
113. http://clinicaltrialsgov/ct2/show/NCT00664677.
114. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule surviving suppressant, induces regression of established human hormonerefractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-21.
115. Iwasa T, Okamoto I, Takezawa K, et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010; 103: 36-42.
116. Nakahara T, Kita A, Yamanaka K, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2010 Dec 14 doi: 101111/j1349-7006201001834x [Epub ahead of print].
117. Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-80.
118. Goga A, Yang D, Tward AD, et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007; 13: 820-7.
119. Cheung HH, Mahoney DJ, Lacasse EC, Korneluk. RGDownregulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res 2009; 69: 7729-38.
120. Liu X, Ryland L, Yang J, Liao A, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia Blood 2010; 116: 4192-201.
121. Wang Z, Cuddy M, Samuel T, et al. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 2004; 279: 48168-76.
122. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
123. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer. Cancer Res 2005; 65: 2378-86.
124. Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005; 105: 4043-50.
125. Cillessen SAc, Reed JC, Welsh K, et al. Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 2008; 111: 369-75.
126. Kater AP, Dicker F, Mangiola M, et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005; 106: 1742-8.
127. Wu TY, Wagner KW, Bursulaya B,et al. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/Caspase-3 interaction. Chem Biol 2003; 10: 759-67
128. Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-26.
129. Bockbrader KM, Tan M, Sun Y. A small molecule Smacmimic compound induces apoptosis and sensitizes TRAILand etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24: 7381-8.
130. Zobel K, Wang L, Varfolomeev E, et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006; 1: 525-33.
131. Sun H, Nikolovska-Coleska Z, Lu J, et al. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 2006; 49: 7916-20.
132. Sun H, Nikolovska-Coleska Z, Chen J, et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg Med Chem Lett 2005; 15: 793-7.
133. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305: 14714.
134. Kashkar H, Haefs C, Shin H, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198: 341-7.
135. Chauhan D, Neri P, Velankar M, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007; 109: 1220-7.
136. Guo F, Nimmanapalli R, Paranawithana S, et al. Ectopic overexpression of second mitochondriaderived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative- (BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002; 99: 3419-26.
137. Kashkar H, Seeger JM, Hombach A, et al. XIAP targeting sensitizes Hodgkin's lymphoma cells for cytolytic T-cell attack. Blood 2006; 108: 3434-40.
138. Jia L, Patwari Y, Kelsey SM, et al. Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene 2003; 22: 1589-99.
139. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-81.
140. Gaither A, Porter D, Yao Y, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007; 67: 11493-8.
141. Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-56.
142. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-93.
143. Hossbach J, Michalsky E, Henklein P, et al. Inhibiting the inhibitors: retro-inverso Smac peptides. Peptides 2009; 30: 2374-9.
144. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408: 1004-8.
145. Sun H, Nikolovska-Coleska Z, Yang CY et al. Structurebased design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 2004; 126: 16686-7.
146. Sun H, Nikolovska-Coleska Z, Yang CY, et al. Structurebased design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem 2004; 47: 4147-50.
147. Sun H, Stuckey JA, Nikolovska-Coleska Z, et al. Structurebased design, synthesis, evaluation and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem 2008; 51: 7169-80.
148. Sun H, Nikolovska-Coleska Z, Lu J, et al. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 2006; 49: 7916-20.
149. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, et al. SM-164: A novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68: 9384-93.
150. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
151. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
152. Petersen SL, Peyton M, Minna JD, Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci U S A 2010; 107: 11936-41.
153. Zobel K, Wang L, Varfolomeev E, et al. Design, Synthesis, and Biological Activity of a Potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006; 1: 525-34.
154. Bockbrader KM, Tan M, Sun Y. A small molecule Smacmimic compound induces apoptosis and sensitizes TRAILand etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24: 7381-8.
155. Palermo, MG et al. Preparation of peptides as inhibitors of IAP. PCT Int Appl WO; 2005097791; 2005.
156. Kapa, PK et al. Process for preparing N-[1-cyclohexyl-2-oxo-2-(6-phenethyloctahydro-pyrrolo[2,3-c]pyridin-1-yl)-ethyl]-2-methylamino-propionamide and related compounds. PCT Int Appl WO 2006107963; 2006.
157. Weisberg E, Kung AL, Wright RD, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007; 6: 1951-61.
158. Cohen F, Alicke B, Elliott LO, et al. Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold. J Med Chem 2009; 52: 1723-30.
159. Chen J, Nikolovska-Coleska Z, Wang G, et al. Design, synthesis and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg Med Chem Lett 2006; 16: 5805-8.
160. Nikolovska-Coleska Z, Xu L, Hu Z, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004; 47: 2430-40.
161. Hu R, Zhu K, Li Y, et al. Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. Med Oncol 2010 Jul 13 [Epub ahead of print].
162. Park CM, Sun C, Olejniczak ET, et al. Non-peptidic small molecule inhibitors of XIAP. Bioorg Med Chem Lett 2005; 15: 771-5.
163. Splan KE, Allen JE, McLendon GL. Biochemical basis for enhanced binding of peptide dimers to X-Linked inhibitor of apoptosis protein. Biochemistry 2007; 46: 11938-44.
164. Wist AD, Gu L, Riedl SJ, et al. Structure-activity based study of the Smac-binding pocket within the BIR3 domain of XIAP. Bioorg Med Chem 2007; 15: 2935-43.
165. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-67.
166. Cheung CH, Chen HH, Cheng LT, et al. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer 2010; 9: 77-87.
167. Probst B L, Liu L, Ramesh V, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner. Cell Death Diff 2010; 17: 1645-54.
168. http://www.news-medical.net/news/20100108/TetraLogic-Pharmaceuticals-commences-its-TL32711-SMAC-mimetic-Phase-1-clinical-trial.aspx.
169. Schyschka L, Rudy A, Jeremias I, et al. Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. Leukemia 2008; 22: 1737-45.
170. Reuter S, Prasad S, Phromnoi K, et al. Thiocolchicoside exhibits anticancer effects through downregulation of NF- {kappa}B pathway and its regulated gene products linked to inflammation and cancer. Cancer Prev Res (Phila) 2010; 3: 1462-72.
171. Gahlot S, Khan MA, Rishi L, Majumdar S. Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol 2010; 80: 1650-61.
172. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 2010; 285: 11498-507.
173. Chao B, Deckwerth TL, Furth PS, et al. Tetrapeptide analogs United States patent PCT/US2005/024700 2006 Feb 16.
174. Loeder S, Zenz T, Schnaiter A, et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009; 69: 8977-86.
175. Capitani S, Miscia S, Marchisio M. Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Res 2009; 19: 1079-89.
176. Iijima M, Momose I, Ikeda D. TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells. Anticancer Res 2009; 29: 977-85.
177. Sung B, Kunnumakkara AB, Sethi G, et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8: 959-70.
178. Wang G, Li G, Liu H, et al. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for Blymphocytic malignancies. J Gene Med 2009; 11: 477-85.
179. Pazhang Y, Ahmadian S, Mahmoudian M, Shafiezadeh M. Berberine-induced apoptosis via decreasing the survivin protein in K562 cell line. Med Oncol 2010 Jun 2 [Epub ahead of print].
180. Kelly KR, Ecsedy J, Medina E, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2010 Nov 21 doi: 101111/j1582-4934 [Epub ahead of print].
181. Carter BZ, Mak DH, Schober WD, et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 2010; 115: 306-14.
182. Maia RC, Vasconcelos FC, de Sá Bacelar T, et al. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells. Invest New Drugs 2010 May 25 [Epub ahead of print].
183. Tong WG, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma J Clin Oncol 2010; 28: 3015-22.
184. Robak T, Szmigielska-Kapłon A, Pluta A, et al. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem 2011; 18: 638-66.
185. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs. 2009; 69: 2415-49.
186. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 10; 29: 551-65.